查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1729602

日本核子造影市场报告（按产品（设备、放射性同位素）、应用（SPECT 应用、PET 应用）和地区划分，2025 年至 2033 年）

Japan Nuclear Imaging Market Report by Product (Equipment, Radioisotope), Application (SPECT Applications, PET Applications), and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 119 Pages | 商品交期: 5-7个工作天内

价格
简介目录

2024 年，日本核子造影市场规模达到 6.03 亿美元。展望未来， IMARC Group预计到 2033 年市场规模将达到 10.4 亿美元，2025-2033 年期间的成长率 (CAGR) 为 6.2%。该市场正在经历显着增长，主要原因是技术进步、老年人口增长和慢性病发病率上升。政府推动早期诊断的倡议、混合成像技术的采用、以及对研发 (R&D) 的大量投资以提高诊断的精度和效率，正在推动市场成长。

日本核子造影市场分析：

  • 主要市场驱动因素：关键市场驱动因素包括癌症和心血管疾病等慢性病盛行率的上升，这需要先进的诊断影像技术。同时，老年人口的成长进一步刺激了对先进影像技术的需求，因为与成年人相比，老年人更容易出现此类疾病。在大量研发投入的支援下，影像设备的技术进步进一步提高了诊断程序的准确性和效率。此外，政府促进早期疾病检测和改善医疗保健基础设施的措施和政策极大地促进了日本核子造影市场的成长。核子医学与其他影像方式结合的混合影像技术的日益普及也为市场带来了积极的前景。
  • 主要市场趋势：主要市场趋势包括 PET/CT 和 SPECT/CT 等混合影像技术的日益普及，这些技术透过结合功能和解剖成像来提高诊断准确性。人们也开始明显转向使用先进的放射性药物，因为这些药物可以提供更好的成像品质和特定的诊断。市场正在经历人工智慧和机器学习融合的显着增长，以改善影像分析并简化工作流程。此外，对个人化医疗的关注正在推动客製化核成像解决方案的发展，进而推动日本核子成像市场的成长。如今，随着人们努力减少辐射暴露和提高成像系统的效率，环境永续性正成为优先事项。
  • 竞争格局：市场的主要参与者正在大力投资研发（R&D）以推出创新的影像技术。如今，公司也在建立策略合作伙伴关係，以扩大其产品组合和市场范围。此外，他们还强调环境永续性，透过创造更有效率、低辐射成像解决方案来满足监管标准和医疗保健需求。
  • 挑战与机会：市场面临各种挑战，例如与先进成像技术和放射性药物相关的高成本，这可能会限制其可及性和可负担性。新的影像剂和设备的监管障碍和严格的审批流程也造成了重大障碍。然而，这些挑战也创造了重大机会。慢性病发病率的上升和老年人口的增加推动了对精确诊断工具的需求。人工智慧和机器学习等技术进步为提高成像精度和效率提供了前景。此外，政府推动早期诊断和个人化医疗的措施也为市场提供了重要的成长途径。产业参与者和医疗机构之间的合作进一步促进了日本核子造影市场的成长和创新。

日本核子造影市场趋势：

慢性病盛行率上升

日本癌症发生率不断上升，需要先进的诊断工具，这使得核子影像对于早期发现、准确分期和监测治疗反应至关重要。根据日本国立医学图书馆发布的报告，自1981年以来，癌症一直是日本最大的死亡原因，占总死亡人数的三分之一。 2022 年新增癌症病例 1,019,000 例，癌症死亡人数 380,400 人。 PET/CT 等技术可提供癌症组织的详细影像，有助于制定个人化治疗方案并改善患者预后。同样，心血管疾病这一主要的健康问题也从 SPECT 和 PET 扫描等核子造影方式中受益匪浅。这些技术有助于评估心肌灌注、检测缺血和评估心臟功能，从而促进及时和精确的干预。对核子造影的日益依赖增强了对这些慢性疾病的管理，有助于改善健康结果并延长患者的生存期。

老年人口不断增加

日本人口老化大大增加了对核子影像服务的需求，因为老年人通常需要频繁进行诊断程序来治疗与年龄相关的健康问题。根据BBC报道，全国资料显示，日本1.25亿人口中，29.1%的人年龄在65岁以上。在日本，预计到2040年，65岁以上的人口将占总人口的34.8％。癌症、心血管疾病和神经系统疾病等疾病在老年人中更为普遍，因此需要先进的影像技术来进行早期发现和准确诊断。此外，与年龄相关的退化性疾病（如阿兹海默症）也可透过核子影像进行早期介入。老年人口的成长推动了日本核子造影市场的成长，确保老年人获得更好的医疗保健结果和生活品质。

政府投资增加

日本政府对医疗保健基础设施的投资对于促进核子造影市场的发展至关重要。这些投资包括为最先进的影像技术和设施提供资金，确保医疗保健提供者能够使用最新的诊断工具。例如，日本健康2025计画旨在改变全球医疗保健，并专注于医疗创新和技术。该国的医疗保健产业正在不断发展，包括硅谷日本创新园区等倡议以及精准医疗和再生医学的进步。日本健康致力于将日本与世界联繫起来，并将其医疗保健产业提升到全球标准。这些进步提高了诊断的准确性和患者护理，推动了核成像的普及。此外，有利的监管政策透过简化新成像技术和放射性药物的审批流程来支持市场的成长。政府推动核子造影研究和开发的措施促进了创新并推动了尖端技术和治疗方法的引进，最终改善了整体医疗保健系统和患者的治疗效果。

日本核子造影市场细分：

按产品分类：

  • 装置
  • 放射性同位素
    • SPECT放射性同位素
      • 锝-99m（TC-99m）
      • 铊-201（TI-201）
      • 镓（Ga-67）
      • 碘（I-123）
      • 其他的
    • PET放射性同位素
      • 氟-18（F-18）
      • 铷-82（RB-82）
      • 其他的

日本核子成像设备市场是该国先进医疗保健基础设施的重要组成部分。关键设备包括单光子发射电脑断层扫描 (SPECT) 和正子断层扫描 (PET) 扫描仪，它们对于诊断癌症、心血管疾病和神经系统疾病等各种疾病至关重要。日本人口老化、慢性病盛行率上升以及影像技术的进步推动了此类设备的需求。此外，成像设备中人工智慧和机器学习的整合提高了诊断的准确性和效率，进一步推动了市场成长。对医疗保健基础设施的持续投资和对早期疾病检测意识的提高，极大地促进了日本核成像设备市场的扩张。

放射性同位素是日本核子造影市场的基础，为 SPECT 和 PET 影像技术提供必要的追踪剂。 SPECT 放射性同位素，例如锝-99m (Tc-99m) 和铊-201 (Tl-201)，因其良好的特性和可用性而被广泛用于心臟、骨骼和肿瘤成像。 PET 放射性同位素，包括氟-18 (F-18) 和铷-82 (Rb-82)，可提供对检测癌症、神经系统疾病和心血管疾病至关重要的高解析度影像。这些疾病的日益普及推动了对 SPECT 和 PET 放射性同位素的需求。日本强大的医疗保健基础设施，加上其对先进核医学研究的重视，支持了这些放射性同位素的广泛应用，确保了精确的诊断和有效的疾病管理。

按应用分类：

  • SPECT 应用
    • 骨科
    • 甲状腺
    • 心臟病学
    • 其他的
  • PET应用
    • 肿瘤学
    • 心臟病学
    • 神经病学
    • 其他的

在日本，SPECT 应用对于诊断和监测各种健康状况至关重要。骨科可以利用 SPECT 影像来检测骨骼异常和骨折。甲状腺影像利用 SPECT 来评估甲状腺功能并检测甲状腺功能亢进或甲状腺癌等疾病。心臟科应用使用 SPECT 来评估心肌灌注和诊断冠状动脉疾病。其他应用包括癫痫和痴呆症的脑部影像。这些疾病的盛行率不断上升，加上 SPECT 技术的进步，推动了日本医疗保健领域对 SPECT 应用的需求，确保了精确的诊断和改善患者的治疗效果。

PET 应用是日本核子造影市场不可或缺的一部分，为各个医疗领域提供高解析度影像。肿瘤学严重依赖 PET 来检测和分期癌症、监测治疗反应和復发。心臟病学应用使用 PET 来评估心肌灌注和活力，有助于诊断和治疗心臟病。神经病学受益于 PET 影像来诊断和评估阿兹海默症和癫痫等神经系统疾病。其他应用包括感染和发炎成像。日本癌症、心血管疾病和神经系统疾病发病率的不断上升，推动了对 PET 应用的需求，以增强早期发现和有效的治疗策略。

日本核子造影市场最新发展：

  • 2024 年 4 月，博莱科集团成立博莱科日本公司，取代合资公司博莱科卫材，在日本建立直接业务。这项搬迁活动在义大利驻东京大使馆举行，恰逢义大利製造全国週。该公司旨在满足日本市场对先进医疗产品和成像技术日益增长的需求。 Bracco Japan 将专注于开发新产品并加强与当地医疗界的关係。
  • 2024 年 4 月，GE 医疗集团在孟加拉为其 A1-Sure 超音波系统启动了一个新的翻新部门，旨在改善医疗服务不足的二线和三线城市的医疗服务。该计划包括高品质的翻新超音波设备，并提供完整的检查、保固和融资选择。此举旨在为大城市以外地区提供可负担的医疗保健解决方案，为当地就业和能力建设创造机会。

本报告回答的关键问题：

  • 日本核子成像市场迄今表现如何？未来几年将如何表现？
  • 日本核子造影市场的驱动因素、限制因素和机会是什么？
  • 每个驱动因素、限制因素和机会对日本核子造影市场有何影响？
  • 主要的区域市场有哪些？
  • 哪些国家代表了日本最具吸引力的核子成像市场？
  • 根据产品，市场是如何分類的？
  • 日本核子造影市场最有吸引力的产品是什么？
  • 根据应用，市场细分情况如何？
  • 日本核子造影市场最有吸引力的应用是什么？
  • 根据地区，市场是如何分類的？
  • 日本核子造影市场中最具吸引力的地区是哪一个？
  • 市场的竞争结构是怎么样的？
  • 日本核子造影市场的主要参与者/公司有哪些？

本报告回答的关键问题：

  • 日本核子成像市场迄今表现如何？未来几年将如何表现？
  • 日本核子造影市场的驱动因素、限制因素和机会是什么？
  • 每个驱动因素、限制因素和机会对日本核子造影市场有何影响？
  • 主要的区域市场有哪些？
  • 哪些国家代表了日本最具吸引力的核子成像市场？
  • 根据产品，市场是如何分類的？
  • 日本核子造影市场最有吸引力的产品是什么？
  • 根据应用，市场细分情况如何？
  • 日本核子造影市场最有吸引力的应用是什么？
  • 根据地区，市场是如何分類的？
  • 日本核子造影市场中最具吸引力的地区是哪一个？
  • 市场的竞争结构是怎么样的？
  • 日本核子造影市场的主要参与者/公司有哪些？

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：日本核子造影市场－简介

  • 概述
  • 市场动态
  • 产业趋势
  • 竞争情报

第五章：日本核子造影市场格局

  • 历史与当前市场趋势（2019-2024）
  • 市场预测（2025-2033）

第六章：日本核子造影市场-细分：依产品

  • 装置
    • 概述
  • 放射性同位素
    • 概述
    • 市场区隔
      • SPECT放射性同位素
        • 锝-99m（TC-99m）
        • 铊-201（TI-201）
        • 镓（Ga-67）
        • 碘（I-123）
        • 其他的
      • PET放射性同位素
        • 氟-18（F-18）
        • 铷-82（RB-82）
        • 其他的

第七章：日本核子造影市场-细分：依应用

  • SPECT 应用
    • 概述
    • 市场区隔
      • 骨科
      • 甲状腺
      • 心臟病学
      • 其他的
  • PET应用
    • 概述
    • 市场区隔
      • 肿瘤学
      • 心臟病学
      • 神经病学
      • 其他的

第 8 章：日本核子造影市场-竞争格局

  • 概述
  • 市场结构
  • 市场参与者定位
  • 最佳获胜策略
  • 竞争仪錶板
  • 公司评估象限

第九章：关键参与者简介

  • Company A
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company B
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company C
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company D
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company E
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events

第 10 章：日本核子造影市场-产业分析

  • 驱动因素、限制因素和机会
    • 概述
    • 驱动程式
    • 限制
    • 机会
  • 波特五力分析
    • 概述
    • 买家的议价能力
    • 供应商的议价能力
    • 竞争程度
    • 新进入者的威胁
    • 替代品的威胁
  • 价值链分析

第 11 章：附录

简介目录
Product Code: SR112025A16049

Japan nuclear imaging market size reached USD 603 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,040 Million by 2033, exhibiting a growth rate (CAGR) of 6.2% during 2025-2033. The market is experiencing significant growth mainly driven by technological advancements, growing geriatric population and increase in incidence of chronic disease. Government initiatives promoting early diagnosis, adoption of hybrid imaging technologies, significant investment in research and development (R&D) to enhance diagnostic precision and efficiency is driving the market growth.

Japan Nuclear Imaging Market Analysis:

  • Major Market Drivers: Key market drivers include the rising in prevalence of chronic disease, such as cancer and cardiovascular diseases, which necessitates advanced diagnostic imaging technologies. In line with this, the growing geriatric population further fuels the demand for advanced imaging technologies as older population are more prone to such conditions as compared to adults. Technological advancements in imaging equipment supported by substantial investment in research and development (R&D) further enhances the accuracy and efficiency of diagnostic procedures. Furthermore, the government initiatives and policies promoting early disease detection and improving healthcare infrastructure significantly boosts the Japan nuclear imaging market growth. The rising adoption of hybrid imaging techniques combining nuclear medicine with other imaging modalities also create a positive outlook for the market.
  • Key Market Trends: Key market trends include the growing adoption of hybrid imaging technologies such as PET/CT and SPECT/CT which offers enhanced diagnostic accuracy by combining functional and anatomical imaging. There is also significant shift towards the use of advanced radiopharmaceuticals which provide better imaging qualities and target specific diagnostics. The market is experiencing a significant rise in integration of artificial intelligence and machine learning to improve image analysis and streamline workflows. Furthermore, the focus on personalized medicine is driving the development of tailored nuclear imaging solutions which in turn is driving the Japan nuclear imaging market growth. Environmental sustainability is becoming a priority nowadays with efforts to reduce radiation exposure and improve efficiency of imaging systems.
  • Competitive Landscape: Key players in the market are heavily investing in research and development (R&D) to introduce innovative imaging technologies. Companies nowadays are also engaging in strategic partnerships and collaborations to expand their product portfolios and market reach. Furthermore, they are emphasizing environmental sustainability by creating more efficient, low radiation imaging solutions in order to meet regulatory standards and address healthcare needs.
  • Challenges and Opportunities: The market faces various challenges such as high costs associated with advanced imaging technologies and radiopharmaceuticals which can limit the accessibility and affordability. Regulatory hurdles and strict approval processes for new imaging agents and equipment also create significant barriers. However, these challenges create significant opportunities as well. The rising incidence of chronic disease and the growing geriatric population is driving the demand for precise diagnostic tools. Technological advancements including artificial intelligence and machine learning offers prospects for improved imaging accuracy and efficiency. Furthermore, government initiatives promoting early diagnosis and personalized medicine also present significant market growth avenues. Collaborations between industry players and in healthcare institutions are further enhancing the Japan nuclear imaging market growth and innovation.

Japan Nuclear Imaging Market Trends:

Rising Prevalence of Chronic Diseases

Rising prevalence of cancer in Japan necessitates advanced diagnostic tool which makes nuclear imaging important for early detection, accurate staging and monitoring treatment responses. According to a report published by National Library of Medicine, cancer has been the leading cause of death in Japan since 1981 accounting for 1/3 of total deaths. There were 1,019,000 new cancer cases and 380,400 cancer deaths in 2022. Techniques like PET/CT provide detailed images of cancerous tissues aiding in personalized treatment plans and improving patient outcomes. Similarly, cardiovascular disease a major health concern benefits significantly from nuclear imaging modalities such as SPECT and PET scans. These techniques help in assessing myocardial perfusion, detecting ischemia, and evaluating cardiac function, thereby facilitating timely and precise interventions. The growing reliance on nuclear imaging enhances the management of these chronic diseases, contributing to better health outcomes and prolonged patient survival.

Rising Geriatric Population

Japan's aging population significantly increases the demand for nuclear imaging services as older adults often require frequent diagnostic procedures for age-related health issues. According to an article published by BBC, national data shows that 29.1% of 125 million population in Japan is aged 65 or older. In Japan, people aged over 65 are expected to account for 34.8% of population by 2040. Conditions such as cancer, cardiovascular diseases and neurological disorders are more prevalent in elderly people which necessitates advanced imaging technologies for early detection and accurate diagnosis. Furthermore, age-related degenerative conditions such as Alzheimer disease benefits from nuclear imaging for early intervention. The rising geriatric demographic drives the Japan nuclear imaging market growth, ensuring better healthcare outcomes and quality of life for older adults.

Increase in Government Investments

Government investments in healthcare infrastructure in Japan are crucial in bolstering the nuclear imaging market. These investments include funding for state-of-the-art imaging technologies and facilities, ensuring that healthcare providers have access to the latest diagnostic tools. For instance, Japan Health 2025 aims to transform global healthcare with a focus on medical innovation and technology. The country's healthcare sector is evolving, with initiatives like the Japan Innovation Campus in Silicon Valley and advancements in Precision Medicine and regenerative medicine. Japan Health aspires to connect Japan with the world and elevate its healthcare industry to global standards. Such advancements improve diagnostic accuracy and patient care, driving the adoption of nuclear imaging. Furthermore, favorable regulatory policies support the market's growth by streamlining the approval process for new imaging technologies and radiopharmaceuticals. Government initiatives promoting research and development in nuclear imaging foster innovation and facilitate the introduction of cutting-edge techniques and treatments, ultimately enhancing the overall healthcare system and patient outcomes.

Japan Nuclear Imaging Market Segmentation:

Breakup by Product:

  • Equipment
  • Radioisotope
    • SPECT Radioisotopes
      • Technetium-99m (TC-99m)
      • Thallium-201 (TI-201)
      • Gallium (Ga-67)
      • Iodine (I-123)
      • Others
    • PET Radioisotopes
      • Fluorine-18 (F-18)
      • Rubidium-82 (RB-82)
      • Others

The Japan nuclear imaging market for equipment is a vital component of the country's advanced healthcare infrastructure. Key equipment includes Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) scanners, which are essential for diagnosing various conditions, including cancer, cardiovascular diseases, and neurological disorders. The demand for such equipment is driven by Japan's aging population, increasing prevalence of chronic diseases, and advancements in imaging technologies. Moreover, the integration of artificial intelligence and machine learning in imaging equipment enhances diagnostic accuracy and efficiency, further propelling market growth. Continuous investments in healthcare infrastructure and rising awareness about early disease detection contribute significantly to the expansion of the nuclear imaging equipment market in Japan.

Radioisotopes are fundamental to Japan's nuclear imaging market, providing the necessary tracers for both SPECT and PET imaging techniques. SPECT radioisotopes, such as Technetium-99m (Tc-99m) and Thallium-201 (Tl-201), are extensively used for cardiac, bone, and tumor imaging due to their favorable properties and availability. PET radioisotopes, including Fluorine-18 (F-18) and Rubidium-82 (Rb-82), offer high-resolution imaging crucial for detecting cancer, neurological disorders, and cardiovascular diseases. The increasing prevalence of these conditions drives the demand for both SPECT and PET radioisotopes. Japan's robust healthcare infrastructure, coupled with its focus on advanced nuclear medicine research, supports the growing utilization of these radioisotopes, ensuring precise diagnostics and effective disease management.

Breakup by Application:

  • SPECT Applications
    • Orthopedics
    • Thyroid
    • Cardiology
    • Others
  • PET Applications
    • Oncology
    • Cardiology
    • Neurology
    • Others

In Japan, SPECT applications are pivotal for diagnosing and monitoring various health conditions. Orthopedics benefits from SPECT imaging in detecting bone abnormalities and fractures. Thyroid imaging utilizes SPECT to assess thyroid function and detect disorders like hyperthyroidism or thyroid cancer. Cardiology applications use SPECT to evaluate myocardial perfusion and diagnose coronary artery disease. Other applications include brain imaging for epilepsy and dementia. The rising prevalence of these conditions, coupled with advancements in SPECT technology, drives the demand for SPECT applications in Japan's healthcare sector, ensuring precise diagnostics and improved patient outcomes.

PET applications are integral to Japan's nuclear imaging market, offering high-resolution imaging for various medical fields. Oncology heavily relies on PET for detecting and staging cancers, monitoring treatment response, and recurrence. Cardiology applications use PET to assess myocardial perfusion and viability, aiding in the diagnosis and management of heart diseases. Neurology benefits from PET imaging in diagnosing and evaluating neurological disorders like Alzheimer's disease and epilepsy. Other applications include infection and inflammation imaging. The increasing incidence of cancer, cardiovascular, and neurological diseases in Japan fuels the demand for PET applications, enhancing early detection and effective treatment strategies.

Competitive Landscape:

  • The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided.
  • The Japan Nuclear Imaging Market is highly competitive, characterized by the presence of various key players. These companies are leading the market through technological innovations, extensive research and development, and strategic collaborations. For instance, in April 2024, FUJIFILM Toyama Chemical and Synplogen entered a strategic business alliance on CDMO services for mRNA therapeutics. This alliance expands CDMO services to cover mRNA sequence design and plasmid DNA synthesis. Synplogen will provide mRNA sequence design and plasmid DNA synthesis services. By integrating expertise in mRNA sequence design and plasmid DNA synthesis, the companies aim to maximize customer value in the mRNA therapeutics industry and support its growth. Additionally, smaller domestic companies and startups are also contributing to market dynamism by introducing niche products and services. The market's competitiveness is further intensified by the increasing adoption of nuclear imaging for early diagnosis and treatment of chronic diseases.

Japan Nuclear Imaging Market Recent Developments:

  • In April 2024, Bracco Group establishes a direct presence in Japan with the launch of Bracco Japan, replacing the joint venture Bracco Eisai. The move is celebrated at the Italian Embassy in Tokyo and coincides with the National Made in Italy Week. The company aims to meet the growing demands for advanced medical products and imaging technologies in the Japanese market. Bracco Japan will focus on developing new products and strengthening relationships with the local medical community.
  • In April 2024, GE HealthCare launched a new refurbishing unit in Bangladesh for its A1-Sure Ultrasound Systems, aiming to improve healthcare access in underserved Tier 2 and Tier 3 cities. The initiative includes high-quality refurbished ultrasound equipment complete with inspections, warranty, and financing options. This move seeks to offer affordable healthcare solutions beyond major cities, creating opportunities for local employment and capacity building.

Key Questions Answered in This Report:

  • How has the Japan nuclear imaging market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the Japan nuclear imaging market?
  • What is the impact of each driver, restraint, and opportunity on the Japan nuclear imaging market?
  • What are the key regional markets?
  • Which countries represent the most attractive Japan nuclear imaging market?
  • What is the breakup of the market based on the product?
  • Which is the most attractive product in the Japan nuclear imaging market?
  • What is the breakup of the market based on the application?
  • Which is the most attractive application in the Japan nuclear imaging market?
  • What is the breakup of the market based on the region?
  • Which is the most attractive region in the Japan nuclear imaging market?
  • What is the competitive structure of the market?
  • Who are the key players/companies in the Japan nuclear imaging market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Nuclear Imaging Market - Introduction

  • 4.1 Overview
  • 4.2 Market Dynamics
  • 4.3 Industry Trends
  • 4.4 Competitive Intelligence

5 Japan Nuclear Imaging Market Landscape

  • 5.1 Historical and Current Market Trends (2019-2024)
  • 5.2 Market Forecast (2025-2033)

6 Japan Nuclear Imaging Market - Breakup by Product

  • 6.1 Equipment
    • 6.1.1 Overview
    • 6.1.2 Historical and Current Market Trends (2019-2024)
    • 6.1.3 Market Forecast (2025-2033)
  • 6.2 Radioisotope
    • 6.2.1 Overview
    • 6.2.2 Historical and Current Market Trends (2019-2024)
    • 6.2.3 Market Segmentation
      • 6.2.3.1 SPECT Radioisotopes
        • 6.2.3.1.1 Technetium-99m (TC-99m)
        • 6.2.3.1.2 Thallium-201 (TI-201)
        • 6.2.3.1.3 Gallium (Ga-67)
        • 6.2.3.1.4 Iodine (I-123)
        • 6.2.3.1.5 Others
      • 6.2.3.2 PET Radioisotopes
        • 6.2.3.2.1 Fluorine-18 (F-18)
        • 6.2.3.2.2 Rubidium-82 (RB-82)
        • 6.2.3.2.3 Others
    • 6.2.4 Market Forecast (2025-2033)

7 Japan Nuclear Imaging Market - Breakup by Application

  • 7.1 SPECT Applications
    • 7.1.1 Overview
    • 7.1.2 Historical and Current Market Trends (2019-2024)
    • 7.1.3 Market Segmentation
      • 7.1.3.1 Orthopedics
      • 7.1.3.2 Thyroid
      • 7.1.3.3 Cardiology
      • 7.1.3.4 Others
    • 7.1.4 Market Forecast (2025-2033)
  • 7.2 PET Applications
    • 7.2.1 Overview
    • 7.2.2 Historical and Current Market Trends (2019-2024)
    • 7.2.3 Market Segmentation
      • 7.2.3.1 Oncology
      • 7.2.3.2 Cardiology
      • 7.2.3.3 Neurology
      • 7.2.3.4 Others
    • 7.2.4 Market Forecast (2025-2033)

8 Japan Nuclear Imaging Market - Competitive Landscape

  • 8.1 Overview
  • 8.2 Market Structure
  • 8.3 Market Player Positioning
  • 8.4 Top Winning Strategies
  • 8.5 Competitive Dashboard
  • 8.6 Company Evaluation Quadrant

9 Profiles of Key Players

  • 9.1 Company A
    • 9.1.1 Business Overview
    • 9.1.2 Product Portfolio
    • 9.1.3 Business Strategies
    • 9.1.4 SWOT Analysis
    • 9.1.5 Major News and Events
  • 9.2 Company B
    • 9.2.1 Business Overview
    • 9.2.2 Product Portfolio
    • 9.2.3 Business Strategies
    • 9.2.4 SWOT Analysis
    • 9.2.5 Major News and Events
  • 9.3 Company C
    • 9.3.1 Business Overview
    • 9.3.2 Product Portfolio
    • 9.3.3 Business Strategies
    • 9.3.4 SWOT Analysis
    • 9.3.5 Major News and Events
  • 9.4 Company D
    • 9.4.1 Business Overview
    • 9.4.2 Product Portfolio
    • 9.4.3 Business Strategies
    • 9.4.4 SWOT Analysis
    • 9.4.5 Major News and Events
  • 9.5 Company E
    • 9.5.1 Business Overview
    • 9.5.2 Product Portfolio
    • 9.5.3 Business Strategies
    • 9.5.4 SWOT Analysis
    • 9.5.5 Major News and Events

10 Japan Nuclear Imaging Market - Industry Analysis

  • 10.1 Drivers, Restraints and Opportunities
    • 10.1.1 Overview
    • 10.1.2 Drivers
    • 10.1.3 Restraints
    • 10.1.4 Opportunities
  • 10.2 Porters Five Forces Analysis
    • 10.2.1 Overview
    • 10.2.2 Bargaining Power of Buyers
    • 10.2.3 Bargaining Power of Suppliers
    • 10.2.4 Degree of Competition
    • 10.2.5 Threat of New Entrants
    • 10.2.6 Threat of Substitutes
  • 10.3 Value Chain Analysis

11 Appendix